The evolution of risk factors for respiratory syncytial virus-related hospitalisation in infants born at 32-35 weeks' gestational age: Time-based analysis using data from the FLIP-2 study

Journal of Perinatal Medicine

Volumn 40, Issue 6, 2012, Pages 685-691

  Carbonell, Xavier ^a   Fullarton, John R ^b   Gooch, Katherine L ^c   Figueras Aloy, Jose ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b Strategen Ltd   (United Kingdom)

^c ABBOTT LABORATORIES   (United States)

Author keywords

Infant; Patient admission; Premature; Respiratory syncytial viruses; Risk factors

Indexed keywords

PALIVIZUMAB;

ACCURACY; AREA UNDER THE CURVE; ARTICLE; BREAST FEEDING; CHILD HOSPITALIZATION; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GESTATIONAL AGE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MATERNAL SMOKING; NONHUMAN; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RISK FACTOR; SEASONAL VARIATION; SEX DIFFERENCE; SIBLING; HOSPITALIZATION; HUMAN RESPIRATORY SYNCYTIAL VIRUS;

GESTATIONAL AGE; HOSPITALIZATION; HUMANS; INFANT; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; RISK FACTORS;

EID: 84869391186     PISSN: 03005577     EISSN: 16193997     Source Type: Journal    
DOI: 10.1515/jpm-2011-0248     Document Type: Article

References (34)

1. American Academy of Pediatrics. Policy statement - modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics. 2009;124: 1694-701.
2. Anderson KS, Mullally VM, Fredrick LM, Campbell AL. Compliance with RSV prophylaxis: global physicians'perspectives. Patient Prefer Adherence. 2009;3: 195-203.
3. Boyce TG, Mellen BG, Mitchel EF Jr, Wright PF, Griffin MR. Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid. J Pediatr. 2000;137: 865-70.
4. Broughton S, Roberts A, Fox G, Pollina E, Zuckerman M, Chaudhry S, et al. Prospective study of healthcare utilisation and respiratory morbidity due to RSV infection in prematurely born infants. Thorax. 2005;60: 1039-44. (Pubitemid 41705474)
5. Carbonell-Estrany X, Figueras-Aloy J, Law BJ; Infeccion Respiratoria Infantil por Virus RespiratorioSincitial Study Group; Pediatric Investigators Collaborative Network on Infections in Canada Study Group. Identifying risk factors for severe respiratory syncytial virus among infants born after 33 through 35 completed weeks of gestation: different methodologies yield consistent findings. Pediatr Infect Dis J. 2004;23:S193-201. (Pubitemid 44146413)
6. Carey MA, Card JW, Voltz JW, Arbes SJ Jr, Germolec DR, Korach KS, et al. It's all about sex: male-female differences in lung development and disease. Trends Endocrinol Metab. 2007;18: 308-13. (Pubitemid 47531957)
7. European Medicine Agency. Synagis European Authorisation; 2011. Available at: http://www.emea.europa.eu/humandocs/Humans/EPAR/synagis/synagis.htm. Accessed 17 October 2010.
8. Feltes TF, Cabalka AK, Meissner HC, Piazza FM, Carlin DA, Top FH Jr, et al.; Cardiac Synagis Study Group. Palivizumab prophylaxis reduces hospitalisation due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr. 2003;143: 532-40. (Pubitemid 37352516)
9. Figueras-Aloy J, Carbonell-Estrany X, Comite de Estandares de la Sociedad Espanola de Neonatologia. [Recommendations for the use of palivizumab in the prevention of respiratory syncytial virus infection in late preterm infants (32(1) to 35(0) weeks of gestation)]. An Pediatr (Barc). 2010;73:98.e1-4.
10. Figueras-Aloy J, Carbonell-Estrany X, Quero J; IRIS Study Group. Case-control study of the risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born at a gestational age of 33-35 weeks in Spain. Pediatr Infect Dis J. 2004;23: 815-20. (Pubitemid 40221022)
11. Figueras-Aloy J, Carbonell-Estrany X, Quero-Jimenez J, Fernández-Colomer B, Guzmán-Cabañas J, Echaniz-Urcelay I, et al., IRIS Study Group. Flip-2 Study. Risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born in Spain at a gestational age of 32 to 35 weeks. Pediatr Infect Dis J. 2008;27: 788-93.
12. Frogel MP, Stewart DL, Hoopes M, Fernandes AW, Mahadevia PJ. A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis. J Manag Care Pharm. 2010;16: 46-58.
13. German Society for Paediatric Infectious Diseases Association (DGPI) Stellungnahmezur Prophylaxe von schweren RSVErkrankungen bei Risikokindern mit Palivizumab; 2011. Available at: http://www.dgpi.de. Accessed January 2011.
14. Henderson J, Hilliard TN, Sherriff A, Stalker D, Al Shammari N, Thomas HM. Hospitalisation for RSV bronchiolitis before 12 months of age and subsequent asthma, atopy and wheeze: a longitudinal birth cohort study. Pediatr Allergy Immunol. 2005;16: 386-92. (Pubitemid 41207478)
15. Horn SD, Smout RJ. Effect of prematurity on respiratory syncytial virus hospital resource use and outcomes. J Pediatr. 2003;143:S133-41. (Pubitemid 37456911)
16. IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalisation from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998;102: 531-7.
17. Instituto Nacional de Estadistica. Censos de Poblacion y Viviendas; 2001. Available at: http://www.ine.es. Accessed February 2011.
18. Jones M. Effect of preterm birth on airway function and lung growth. Paediatr Respir Rev. 2009;10(Suppl 1): 9-11.
19. Law BJ, Langley JM, Allen U, Paes B, Lee DS, Mitchell I, et al. The Pediatric Investigators Collaborative Network on Infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation. Pediatr Infect Dis J. 2004;23: 806-14. (Pubitemid 40221021)
20. Palmer L, Hall CB, Katkin JP, Shi N, Masaquel AS, McLaurin KK, et al. Healthcare costs within a year of respiratory syncytial virus among Medicaid infants. Ped Pulmon. 2010;45: 772-81.
21. Palmer L, Hall CB, Katkin JP, Shi N, Masaquel AS, McLaurin KK, et al. Respiratory outcomes, utilization and costs 12 months following a respiratory syncytial virus diagnosis among commercially insured late-preterm infants. Curr Med Red Opin. 2011;27: 403-12.
22. Rondini G, Macagno F, Barberi I. Raccomandazionidella Societa Italiana di Neonatologia per la prevenzionedellemalattie da virus respiratoriosinciziale (VRS). Acta Neonatol. 2004;1: 1-11.
23. Sampalis JS. Morbidity and mortality after RSV-associated hospitalizations among premature Canadian infants. J Pediatr. 2003;143:S150-6. (Pubitemid 37456913)
24. Sampalis JS, Langley J, Carbonell-Estrany X, Paes B, O'Brien K, Allen U, et al. Development and validation of a risk factor scoring tool to predict respiratory syncytial virus hospitalization in premature infants born at 33 through 35 completed weeks of gestation. Med Decis Making. 2008;28: 471-80. (Pubitemid 351989998)
25. Sigurs N. A cohort of children hospitalised with acute RSV bronchiolitis: impact on later respiratory disease. Paediatr Resp Rev. 2002;3: 177-83. (Pubitemid 35314878)
26. Sigurs N, Bjarnason R, Sigurbergsson F, Kjellman B. Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7. Am J Resp Crit Care Med. 2000;161: 1501-7. (Pubitemid 30329018)
27. Sigurs N, Bjarnason R, Sigurbergsson F, Kjellman B, Bjorksten B. Asthma and immunoglobulin E antibodies after respiratory syncytial virus bronchiolitis: a prospective cohort study with matched controls. Pediatrics. 1995;95: 500-5.
28. Sigurs N, Gustafsson PM, Bjarnason R, Lundberg F, Schmidt S, Sigurbergsson F, et al. Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13. Am J Crit Care Respir Med. 2005;171: 137-41. (Pubitemid 40105412)
29. Simoes EA, Carbonell-Estrany X, Fullarton JR, Liese JG, Figueras-Aloy J, Doering G, et al. A predictive model for respiratory syncytial virus (RSV) hospitalisation of premature infants born at 33-35 weeks of gestational age, based on data from the Spanish FLIP study. Respir Res. 2008;9:78.
30. Stein RT, Sherrill D, Morgan WJ, Holberg CJ, Halonen M, Taussig LM, et al. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet. 1999;354: 541-5. (Pubitemid 29381367)
31. Subramanian KN, Weisman LE, Rhodes T, Ariagno R, Sanchez PJ, Steichen J, et al. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with brochopulmonary dysplasia. Pediatr Infect Dis J. 1998;17: 110-15. (Pubitemid 28096007)
32. Thwaites R, Edwards K, Buchan S. Reducing the burden of respiratory syncytial virus: an audit of the use of palivizumab prophylaxis in the UK during the September 2001 - March 2002 RSV season. J Neonatal Nurs. 2008;14: 116-23.
33. US Census Bureau. American Community Survey 5-year estimates 2005-2009, 2010. Available at: http://factfinder2.census. gov/. Accessed February 2011.
34. World Health Organization (WHO). The optimal duration of breastfeeding. Report of an expert consultation. Geneva: WHO; 2001 [updated Mar 2001]. Available at: http://www.who.int. Accessed January 2011.